[Ip-health] The variables in Dr. Peter Bach's Drug Abacus
fiar at verizon.net
Fri Jun 19 13:04:34 PDT 2015
I think patent law should be reformed substantial to, among other things, preclude health-related inventions (drugs, devices, diagnostics) from being used to reward investors. Privatizing R&D has been an unmitigated disaster for both discovery and access.
Patents were meant to reward DISCOVERERS, not investors or bloated CEOs, or lawyers or absurd licensing fees. Discoverers, with a reasonable markup in wealthy nations (maybe 10X manufacturing) and at-cost for LMC and middle-income countries, could make out just fine and get plenty of incentives. This would permit further open-source efforts that clearly identify individuals or teams who contributed the most to the work. Transparent clinical trials funded in collaborative ways by governments would assure patients' risks and contributions are rewarded with truth, medicine and science rather than marketing lies and distortions.
George M. Carter
On Jun 19, 2015, at 3:41 PM, Ruth Lopert wrote:
> I have to disagree. Novel approaches should only be rewarded if they
> deliver enhanced outcomes - as would be the case in other industries. We
> should be rewarding the results, not the enterprise
> On Fri, Jun 19, 2015 at 3:35 PM, Jamie Love <james.love at keionline.org>
>> On Fri, Jun 19, 2015 at 3:31 PM, Ruth Lopert <ruth.lopert at gmail.com>
>>> There is no inherent value in novelty. There are plenty of examples of
>>> drugs with novel mechanisms of action that are no more effective and even
>>> less effective than drugs in the classes that preceded them. Innovation
>>> that addresses an unmet or inadequately met clinical need is of value, but
>>> not novelty per se,
>> Ruth, I think there is a both a value associated with novelty, and
>> risk. Novel approaches may expand the tools available and stimulate new
>> research paths. But novel approaches are probably also more risky, and
>> might benefit from higher rewards, all other things equal or relative.
More information about the Ip-health